Emotional distress – European Clinical Trials Information Network https://clinicaltrials.eu Bridging Patients with Clinical Trials Thu, 18 Jun 2026 04:07:27 +0000 en-US hourly 1 https://wordpress.org/?v=7.0 https://clinicaltrials.eu/wp-content/uploads/2024/12/cropped-EU_icon-32x32.png Emotional distress – European Clinical Trials Information Network https://clinicaltrials.eu 32 32 A Study of Oxytocin Nasal Spray to Reduce Psychological Stress in Women Who Have Recovered from Breast Cancer https://clinicaltrials.eu/trial/a-study-of-oxytocin-nasal-spray-to-reduce-psychological-stress-in-women-who-have-recovered-from-breast-cancer/ Wed, 29 Apr 2026 15:06:58 +0000 https://clinicaltrials.eu/trial/a-study-of-oxytocin-nasal-spray-to-reduce-psychological-stress-in-women-who-have-recovered-from-breast-cancer/ This study focuses on individuals who have survived breast cancer and examines how oxytocin nasal spray might help reduce stress levels after cancer treatment. Oxytocin is a naturally occurring hormone in the body that may have stress-reducing properties. The study will evaluate whether this treatment can help improve emotional well-being in people who have completed their cancer therapy.

During the study, participants will receive either oxytocin nasal spray or a placebo nasal spray containing salt water. The treatment will be given through the nose for up to 5 days. Throughout the study period, participants will complete various questionnaires about their stress levels, emotional state, sleep quality, and thinking abilities. They will also perform some computer-based tasks to assess their cognitive function.

The study aims to understand if using oxytocin nasal spray can help reduce psychological distress that many people experience after breast cancer treatment. The research will measure changes in stress levels, anxiety, depression, and overall quality of life to determine if this treatment approach could be beneficial for breast cancer survivors.

]]> Study on Oxytocin and Mindfulness Training for Reducing Stress in Adults with Psychological Distress https://clinicaltrials.eu/trial/study-on-oxytocin-and-mindfulness-training-for-reducing-stress-in-adults-with-psychological-distress/ Wed, 29 Apr 2026 15:03:30 +0000 https://clinicaltrials.eu/trial/study-on-oxytocin-and-mindfulness-training-for-reducing-stress-in-adults-with-psychological-distress/ This clinical trial is focused on understanding how the combination of the hormone oxytocin and mindfulness training can help reduce stress in adults experiencing psychological distress. Psychological distress refers to feelings of anxiety, depression, or stress that can affect daily life. The study will use a nasal spray containing oxytocin, a naturally occurring hormone known for its role in social bonding and stress regulation.

The purpose of the study is to see if using oxytocin together with mindfulness training is more effective in managing stress than using either approach alone. Mindfulness training involves exercises that help individuals focus on the present moment, which can improve emotional well-being. Participants will receive either the oxytocin nasal spray or a placebo during mindfulness sessions to compare the effects on stress levels.

Throughout the study, participants will be asked to complete various questionnaires to assess their levels of stress, mood, and quality of life. These assessments will help researchers understand the impact of the treatment on psychological distress. The study aims to provide insights into how combining oxytocin with mindfulness training might enhance stress management in individuals with heightened stress complaints.

]]> Study of psilocybin therapy for psychological distress in patients with COPD, ALS, multiple sclerosis, or atypical Parkinson’s disorders https://clinicaltrials.eu/trial/psilocybin-therapy-for-reducing-depression-in-patients-with-copd-als-ms-or-atypical-parkinsons-disorder/ Wed, 29 Apr 2026 14:57:32 +0000 https://clinicaltrials.eu/trial/psilocybin-therapy-for-reducing-depression-in-patients-with-copd-als-ms-or-atypical-parkinsons-disorder/ This study focuses on testing psilocybin therapy in patients with several progressive conditions including Chronic Obstructive Pulmonary Disease (COPD), Amyotrophic Lateral Sclerosis (ALS), Multiple Sclerosis (MS), and Atypical Parkinson Disorder (APD) who are experiencing psychological distress. The study will use different doses of psilocybin capsules (1 mg, 15 mg, and 25 mg) given by mouth to understand how this treatment might help reduce depression symptoms in these patients.

The purpose of this research is to evaluate whether medium to high doses of psilocybin therapy are safe and effective in reducing depression symptoms compared to low doses in patients with these conditions. Participants will receive two doses of the medication during the study, with evaluations of their depression symptoms occurring before treatment and six weeks after the second dose.

During the study, patients will be monitored for changes in their psychological well-being, including their ability to cope with end-of-life concerns, overall quality of life, and general mental health. The study will also look at how the treatment affects the stress levels and daily responsibilities of those caring for the patients. The treatment period will last approximately two months, with follow-up evaluations to track the participants’ progress.

]]>